Catasys, Inc. (OTCQB: CATS), provider of proprietary health management services to health insurers and employers, today announced that Omar Manejwala, M.D., Senior VP and Chief Medical Officer of Catasys, will deliver a presentation at the American Society of Addiction Medicine (ASAM). The 44th annual medical-scientific conference, “New Treatments in Addiction Medicine,” will be held from April 25 – 28, 2013, in Chicago, Illinois.
Dr. Manejwala oversees medical affairs at Catasys. His presentation on Friday, April 26th from 2:30–4:30pm will focus on innovative ways of generating clinical improvements in substance dependent populations to drive reductions in their overall healthcare costs, and is entitled “Combining Predictive Analytics, Outreach, Evidence Based Treatment, Case Management and Monitoring to Generate Clinical Outcome Driven Cost Reductions in High Cost Substance Dependent Populations.”
Catasys has built its reputation as a substance dependence expert based upon the success of its OnTrakTM program – which was designed to improve member health and lower costs by utilizing patient centric treatment that integrates evidence based medical and psychosocial interventions along with care coaching in a 52 week outpatient program. OnTrak is currently improving member health and is demonstrating with several health insurers impressive results as evidenced by reduced inpatient and emergency department utilization driving a reduction in total health care costs of more than 50% for enrolled members.
ASAM is a professional society representing more than 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promotion the appropriate role of physicians in the care of patients with addictions. www.asam.org.
About Catasys, Inc.
Catasys, Inc. provides specialized health management services to health plans and employers through a network of licensed and company managed health care providers. The Catasys substance dependence program improves member health, thereby lowering overall costs. The proprietary program addresses substance dependence as a chronic disease, focusing on the whole health of the member. The program delivers integrated medical and psychosocial interventions in combination with long-term care coaching. For further information, please visit www.catasyshealth.com.
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history, lack of outcomes and statistically significant formal research studies, difficulty enrolling members in our programs, the risk that treatment programs might not be effective, difficulty in developing, exploiting and protecting proprietary technologies and intense competition and substantial regulation in the health care industry. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov.Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Terri MacInnis, Dir. of Investor Relations